Drug Landscape ›
Control 1 ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 13
Most-reported reactions
Pyrexia — 2 reports (15.38%) Respiratory Depression — 2 reports (15.38%) Weight Decreased — 2 reports (15.38%) Abnormal Dreams — 1 report (7.69%) Application Site Pain — 1 report (7.69%) Application Site Pruritus — 1 report (7.69%) Delirium — 1 report (7.69%) Drug Interaction — 1 report (7.69%) Headache — 1 report (7.69%) Hepatic Encephalopathy — 1 report (7.69%)
Source database →
Control 1 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Control 1 approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Control 1 in United States?
Aydin Adnan Menderes University is the originator. The local marketing authorisation holder may differ — check the official source linked above.